Filter
1344
Text search:
drug
approval
Featured
95
392
Language
Document type
774
248
173
63
39
24
15
4
3
1
Countries / Regions
90
47
42
39
37
34
32
32
28
27
25
24
24
23
22
21
21
20
18
14
14
13
13
12
12
12
11
9
8
8
8
7
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
613
105
41
38
32
31
13
Toolboxes
130
112
102
72
72
64
54
25
24
22
18
17
16
15
12
11
10
9
9
7
5
4
4
1
1
Document No. : FDA/SMC/SMD/GL-RAR/2013/01
MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
These guidelines for the National Pharmacovigilance and Medicine Information System in Rwanda have been developed to ensure that safe, efficacious and quality medicines are made available to all Rwandans.
The overall goal of the programme, to reduce the malaria morbidity and mortality by 75% (using 2012 as baseline) by the year 2020, continued to be pursued in 2014. The following areas were identified as some of the priorities for the year: Malaria Case Management under which we have Malaria in Pregn
...
The WHO Framework for the clinical evaluation of devices for male circumcision
outlines a multi-phase process to ensure the safety, efficacy, and acceptability of new devices, especially for use in resource-limited settings
African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
In 2018 and early 2019, the WHO Regional Office for Europe’s cultural contexts of health and well-being project worked alongside the University of Exeter’s WHO Collaborating Centre on Culture and Health, the Minsk Regional Centre for Psychiatry and Addiction, and the Institute of Mental Health o
...
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
2014-2020, Draft March 2014
